CanSino Biologics shareholders approve governance and director changes

CanSino Biologics Inc. announced that all resolutions proposed at its 2025 Second Extraordinary General Meeting (EGM) on November 27, 2025, were duly passed by poll. Key approvals included amendments to the Articles of Association, with resolutions 4.01 and 4.02 voted by cumulative voting, effective November 27, 2025.

During the EGM, Mr. Man CHO and Ms. Xuefeng JI were elected as independent non-executive directors for the third session of the Board of Directors, with their terms commencing immediately. Following the EGM, the Board of Directors resolved to adjust the composition of its committees, effective November 27, 2025, until the expiry of the third session's term. Ms. Xuefeng JI will now chair the nomination committee, Mr. Man CHO will chair the remuneration and assessment committee, and Mr. Yiu Leung Andy CHEUNG will chair the audit committee.

The total number of shares in issue for calculating EGM attendance was 247,043,801, with 91,587,182 shares present (37.07%). The company's registered capital is RMB247,449,899, consisting entirely of ordinary shares.